Evidence map›Paper›PMID 37641108›Full record

ArticleInfectious diseases of poverty2023

High efficacy of chlorfenapyr-based net Interceptor

Magellan Tchouakui, Riccado F Thiomela, Elysee Nchoutpouen, Benjamin D Menze, Cyrille Ndo, Dorothy Achu, Raymond N Tabue, Flobert Njiokou, Ateba Joel, Charles S Wondji

Open access · goldAbstract read
In one paragraph

Article in Infectious diseases of poverty, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Functional Validation of Endogenous Redox PartnerInternational journal of molecular sciences · 2024
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Magellan TchouakuiCentre for Research in Infectious Diseases (CRID), P.O. Box 13501, Yaoundé, Cameroon. magellan.tchouakui@crid-cam.net.ORCID http://orcid.org/0000-0002-1683-8057
Riccado F ThiomelaCentre for Research in Infectious Diseases (CRID), P.O. Box 13501, Yaoundé, Cameroon.
Elysee NchoutpouenCentre for Research in Infectious Diseases (CRID), P.O. Box 13501, Yaoundé, Cameroon.
Benjamin D MenzeCentre for Research in Infectious Diseases (CRID), P.O. Box 13501, Yaoundé, Cameroon.
Cyrille NdoCentre for Research in Infectious Diseases (CRID), P.O. Box 13501, Yaoundé, Cameroon.
Dorothy AchuMinistry of Public Health, National Malaria Control Programme, P.O. Box 14386, Yaounde, Cameroon.
Raymond N TabueMinistry of Public Health, National Malaria Control Programme, P.O. Box 14386, Yaounde, Cameroon.
Flobert NjiokouDepartment of Animal Biology and Physiology, Faculty of Science, University of Yaoundé 1, P.O. Box 812, Yaoundé, Cameroon.
Ateba JoelMinistry of Public Health, National Malaria Control Programme, P.O. Box 14386, Yaounde, Cameroon.
Charles S WondjiCentre for Research in Infectious Diseases (CRID), P.O. Box 13501, Yaoundé, Cameroon. charles.wondji@lstmed.ac.uk.
Ministry of Public Health · CMMinistry of Scientific Research and Innovation · CMUniversité de Yaoundé I · CMLiverpool School of Tropical Medicine · GBPan African Institute for Development · CMUniversity of Douala · CM

Funding

MRF MR/PO27873/1Wellcome TrustWellcome Trust 217188/Z/19/Z
6 · The paper itself

Abstract

backgroundThe increasing reports of resistance to pyrethroid insecticides associated with reduced efficacy of pyrethroid-only interventions highlight the urgency of introducing new non-pyrethroid-only control tools. Here, we investigated the performance of piperonyl-butoxide (PBO)-pyrethroid [Permanet 3.0 (P3.0)] and dual active ingredients (AI) nets [Interceptor G2 (IG2): containing pyrethroids and chlorfenapyr and Royal Guard (RG): containing pyrethroids and pyriproxyfen] compared to pyrethroid-only net Royal Sentry (RS) against pyrethroid-resistant malaria vectors in Cameroon.

methodsThe efficacy of these tools was firstly evaluated on Anopheles gambiae s.l. and Anopheles funestus s.l. from Gounougou, Mibellon, Mangoum, Nkolondom, and Elende using cone/tunnel assays. In addition, experimental hut trials (EHT) were performed to evaluate the performance of unwashed and 20 times washed nets in semi-field conditions. Furthermore, pyrethroid-resistant markers were genotyped in dead vs alive, blood-fed vs unfed mosquitoes after exposure to the nets to evaluate the impact of these markers on net performance. The XLSTAT software was used to calculate the various entomological outcomes and the Chi-square test was used to compare the efficacy of various nets. The odds ratio and Fisher exact test were then used to establish the statistical significance of any association between insecticide resistance markers and bed net efficacy.

resultsInterceptor G2 was the most effective net against wild pyrethroid-resistant An. funestus followed by Permanet 3.0. In EHT, this net induced up to 87.8% mortality [95% confidence interval (CI): 83.5-92.1%) and 55.6% (95% CI: 48.5-62.7%) after 20 washes whilst unwashed pyrethroid-only net (Royal Sentry) killed just 18.2% (95% CI: 13.4-22.9%) of host-seeking An. funestus. The unwashed Permanet 3.0 killed up to 53.8% (95% CI: 44.3-63.4%) of field-resistant mosquitoes and 47.2% (95% CI: 37.7-56.7%) when washed 20 times, and the Royal Guard 13.2% (95% CI: 9.0-17.3%) for unwashed net and 8.5% (95% CI: 5.7-11.4%) for the 20 washed net. Interceptor G2, Permanet 3.0, and Royal Guard provided better personal protection (blood-feeding inhibition 66.2%, 77.8%, and 92.8%, respectively) compared to pyrethroid-only net Royal Sentry (8.4%). Interestingly, a negative association was found between kdrw and the chlorfenapyr-based net Interceptor G2 (χ

conclusionsThe high mortality recorded with Interceptor G2 against pyrethroid-resistant malaria vectors in this study provides first semi-field evidence of high efficacy against these major malaria vectors in Cameroon encouraging the implementation of this novel net for malaria control in the country. However, the performance of this net should be established in other locations and on other major malaria vectors before implementation at a large scale.

Indexed as

AnophelesMalariaAnimalsCameroonMacrolidesMosquito VectorsPyrethrinschlorfenapyrMacrolidesmilbemycin oximePyrethrinsAnophelesDual active ingredient netsInsecticide resistanceInterceptor G2Malaria

Identifiers

PMID37641108
PMCPMC10463949
OpenAlexW4386253091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.